PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW
Objective: This systematic review aims to evaluate the influence of genetic polymorphisms on clinical outcomes in immunoprophylaxis with Calcineurin Inhibitors (CNIs) in patients undergoing hematopoietic cell transplantation. Materials and methods: Registered in PROSPERO on 09/03/2024 (CRD4202451709...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924020364 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182144033292288 |
|---|---|
| author | LC Costa-Junior DR Freitas-Alves AML Leão PS Araújo HAV Monteiro MCR Moreira MB Visacri TSF Seixas PCJL Santos |
| author_facet | LC Costa-Junior DR Freitas-Alves AML Leão PS Araújo HAV Monteiro MCR Moreira MB Visacri TSF Seixas PCJL Santos |
| author_sort | LC Costa-Junior |
| collection | DOAJ |
| description | Objective: This systematic review aims to evaluate the influence of genetic polymorphisms on clinical outcomes in immunoprophylaxis with Calcineurin Inhibitors (CNIs) in patients undergoing hematopoietic cell transplantation. Materials and methods: Registered in PROSPERO on 09/03/2024 (CRD42024517094) and constructed following PRISMA 2020 guidelines, the review involved a comprehensive search across databases including PubMed, MEDLINE, LILACS, Bireme, Medcarib, Paho-iris, Wholis, Scopus, Web of Science, Embase, and Cochrane. The search limited to English articles published from 2013 to 2024, used terms related to “genetic polymorphisms”, “calcineurin inhibitors”, “hematopoietic cell transplantation”, “tacrolimus”, and “cyclosporine”, combined with Boolean operators. The last search was conducted on February 9, 2024. Inclusion criteria encompassed studies on humans addressing the pharmacogenetics of CNIs, while exclusion criteria included studies on other types of transplants and reviews. Results were saved in RIS format and analyzed using Rayyan platform by three independent reviewers. This study was supported by the CAPES Brazil ‒ Funding Code 001. Results and discussion: Out of 301 identified studies, 226 were screened after removing duplicates, and 19 were included. Most studies were from Asia (60%), followed by North America (35%) and Europe (5%). Among the included studies, 60% focused on tacrolimus (FK), 30% on cyclosporine (CSA), and 10% on both. The total patient number was 1,746, with 684 (39%) females and 1,062 males (60%). Age distribution varied: 60% adults, 20% pediatrics, and 20% both. Median ages were 52.5 (35‒61) for adults and 8.0 (6‒8) for pediatrics. Initial FK doses ranged from 0.01 mg/kg/day to 0.03 mg/kg/day, and CSA doses from 1.5 mg/kg/day to 3 mg/kg/day. The outcomes assessed were: 60% Pharmacokinetics (PK) of FK, 30% PK of CSA, and 10% both. FK PK was the most common outcome, assessed in 12 studies. Graft-Versus-Host Disease (GVHD) was analyzed in 9 studies (47%), and Acute Kidney Injury (AKI) was addressed in 6 studies (30%). Regarding genetic polymorphisms, key genes studied were: CYP3A5 (90%), ABCB1 (65%), CYP3A4 (45%), ABCC2 (15%), ABCG2 (10%), and ABCC1 (5%). The CYP3A5 3*/3* genotype was associated with higher FK levels and a higher concentration/dose (C/D) ratio, as well as a lower adjusted dose and increased AKI risk. Variants in ABCB1, such as C2677T, were linked to higher FK concentrations and increased toxicity risk, but ABCB1’s influence on CSA PK was not observed. The study of pediatric patients in China found that the clearance rate of CSA increased by 24.5% in carriers of the T allele of CYP3A4*1G compared to those with the CC allele. A French study has found polymorphisms in ABCC1, ABCC2, ATIC, and NFATC1 genes were strongly associated with severe a GVHD risk, with multiple SNPs indicating high disease severity risk. CYP3A5 and CYP3A4 genotypes and expression affect FK PK and dosing, with effects varying between intravenous and oral administration, and coadministration with antifungal azoles may increase toxicity in certain genotypes. Conclusion: This review highlights the significant impact of genetic polymorphisms on FK and CSA PK on effectiveness in hematopoietic cell transplantation, underscoring the need for personalized dosing approaches. Notable associations were found with CYP3A5, ABCB1, and CYP3A4 polymorphisms, among others, on implications for plasma levels and toxicity risks. |
| format | Article |
| id | doaj-art-62db09def48449bcbe5a6bcf32a52709 |
| institution | OA Journals |
| issn | 2531-1379 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-62db09def48449bcbe5a6bcf32a527092025-08-20T02:17:41ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-10-0146S1000S100110.1016/j.htct.2024.09.1703PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEWLC Costa-Junior0DR Freitas-Alves1AML Leão2PS Araújo3HAV Monteiro4MCR Moreira5MB Visacri6TSF Seixas7PCJL Santos8Programa de Pós-Graduação em Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil; Centro de Transplante de Medula Óssea, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA-RJ), Rio de Janeiro, RJ, BrazilEscola Nacional de Saúde Pública Sérgio Arouca, Fundação Osvaldo Cruz (ENSP-FIOCRUZ), Rio de Janeiro, RJ, BrazilPrograma de Terapia Celular e Gênica, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, BrazilUniversidade do Grande Rio (Unigranrio), Duque de Caxias, RJ, BrasilDivisão de Pesquisa Clínica, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, BrazilCentro de Transplante de Medula Óssea, Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA-RJ), Rio de Janeiro, RJ, BrazilFaculdade de Ciências Farmacêuticas, Universidade de São Paulo (FCF-USP), São Paulo, SP, BrazilPrograma de Pós-Graduação em Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, BrazilPrograma de Pós-Graduação em Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, BrazilObjective: This systematic review aims to evaluate the influence of genetic polymorphisms on clinical outcomes in immunoprophylaxis with Calcineurin Inhibitors (CNIs) in patients undergoing hematopoietic cell transplantation. Materials and methods: Registered in PROSPERO on 09/03/2024 (CRD42024517094) and constructed following PRISMA 2020 guidelines, the review involved a comprehensive search across databases including PubMed, MEDLINE, LILACS, Bireme, Medcarib, Paho-iris, Wholis, Scopus, Web of Science, Embase, and Cochrane. The search limited to English articles published from 2013 to 2024, used terms related to “genetic polymorphisms”, “calcineurin inhibitors”, “hematopoietic cell transplantation”, “tacrolimus”, and “cyclosporine”, combined with Boolean operators. The last search was conducted on February 9, 2024. Inclusion criteria encompassed studies on humans addressing the pharmacogenetics of CNIs, while exclusion criteria included studies on other types of transplants and reviews. Results were saved in RIS format and analyzed using Rayyan platform by three independent reviewers. This study was supported by the CAPES Brazil ‒ Funding Code 001. Results and discussion: Out of 301 identified studies, 226 were screened after removing duplicates, and 19 were included. Most studies were from Asia (60%), followed by North America (35%) and Europe (5%). Among the included studies, 60% focused on tacrolimus (FK), 30% on cyclosporine (CSA), and 10% on both. The total patient number was 1,746, with 684 (39%) females and 1,062 males (60%). Age distribution varied: 60% adults, 20% pediatrics, and 20% both. Median ages were 52.5 (35‒61) for adults and 8.0 (6‒8) for pediatrics. Initial FK doses ranged from 0.01 mg/kg/day to 0.03 mg/kg/day, and CSA doses from 1.5 mg/kg/day to 3 mg/kg/day. The outcomes assessed were: 60% Pharmacokinetics (PK) of FK, 30% PK of CSA, and 10% both. FK PK was the most common outcome, assessed in 12 studies. Graft-Versus-Host Disease (GVHD) was analyzed in 9 studies (47%), and Acute Kidney Injury (AKI) was addressed in 6 studies (30%). Regarding genetic polymorphisms, key genes studied were: CYP3A5 (90%), ABCB1 (65%), CYP3A4 (45%), ABCC2 (15%), ABCG2 (10%), and ABCC1 (5%). The CYP3A5 3*/3* genotype was associated with higher FK levels and a higher concentration/dose (C/D) ratio, as well as a lower adjusted dose and increased AKI risk. Variants in ABCB1, such as C2677T, were linked to higher FK concentrations and increased toxicity risk, but ABCB1’s influence on CSA PK was not observed. The study of pediatric patients in China found that the clearance rate of CSA increased by 24.5% in carriers of the T allele of CYP3A4*1G compared to those with the CC allele. A French study has found polymorphisms in ABCC1, ABCC2, ATIC, and NFATC1 genes were strongly associated with severe a GVHD risk, with multiple SNPs indicating high disease severity risk. CYP3A5 and CYP3A4 genotypes and expression affect FK PK and dosing, with effects varying between intravenous and oral administration, and coadministration with antifungal azoles may increase toxicity in certain genotypes. Conclusion: This review highlights the significant impact of genetic polymorphisms on FK and CSA PK on effectiveness in hematopoietic cell transplantation, underscoring the need for personalized dosing approaches. Notable associations were found with CYP3A5, ABCB1, and CYP3A4 polymorphisms, among others, on implications for plasma levels and toxicity risks.http://www.sciencedirect.com/science/article/pii/S2531137924020364 |
| spellingShingle | LC Costa-Junior DR Freitas-Alves AML Leão PS Araújo HAV Monteiro MCR Moreira MB Visacri TSF Seixas PCJL Santos PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW Hematology, Transfusion and Cell Therapy |
| title | PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW |
| title_full | PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW |
| title_fullStr | PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW |
| title_full_unstemmed | PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW |
| title_short | PHARMACOGENETICS OF CALCINEURIN INHIBITORS IN HEMATOPOIETIC CELL TRANSPLANTATION: A SYSTEMATIC REVIEW |
| title_sort | pharmacogenetics of calcineurin inhibitors in hematopoietic cell transplantation a systematic review |
| url | http://www.sciencedirect.com/science/article/pii/S2531137924020364 |
| work_keys_str_mv | AT lccostajunior pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT drfreitasalves pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT amlleao pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT psaraujo pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT havmonteiro pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT mcrmoreira pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT mbvisacri pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT tsfseixas pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview AT pcjlsantos pharmacogeneticsofcalcineurininhibitorsinhematopoieticcelltransplantationasystematicreview |